Edition:
India

Glaukos Corp (GKOS.N)

GKOS.N on New York Stock Exchange

42.09USD
20 Jul 2018
Change (% chg)

$0.26 (+0.62%)
Prev Close
$41.83
Open
$41.98
Day's High
$42.43
Day's Low
$41.79
Volume
132,265
Avg. Vol
122,744
52-wk High
$45.00
52-wk Low
$23.10

Latest Key Developments (Source: Significant Developments)

Glaukos Announces FDA Approval For The Istent Inject Trabecular Micro-Bypass System
Monday, 25 Jun 2018 

June 25 (Reuters) - Glaukos Corp ::GLAUKOS ANNOUNCES FDA APPROVAL FOR THE ISTENT INJECT® TRABECULAR MICRO-BYPASS SYSTEM.GLAUKOS CORP - RECEIVED PREMARKET APPROVAL FROM U.S. FDA FOR ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM.GLAUKOS CORP - INTENDS TO COMMENCE INITIAL COMMERCIAL LAUNCH ACTIVITIES LATER IN Q3.  Full Article

Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Glaukos Corp ::GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT.GLAUKOS CORP - COMPANY PREPARES TO COMMENCE PHASE III U.S. IND STUDY IN FIRST HALF OF 2018.GLAUKOS CORP - COMPANY BEGINS PROCESS FOR IDOSE TRAVOPROST REGULATORY APPROVAL IN EUROPE AND JAPAN.GLAUKOS CORP - CONDUCTED A PRODUCTIVE END-OF-PHASE II MEETING WITH FDA IN LATE 2017.  Full Article

Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Glaukos Corp ::GLAUKOS SUBMITS IDE APPLICATION TO FDA TO STUDY ISTENT INFINITE™ TRABECULAR MICRO-BYPASS SYSTEM.GLAUKOS CORP - ‍SUBMITTED IDE APPLICATION TO FDA SEEKING AUTHORIZATION TO STUDY ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM​.  Full Article

Glaukos Announces Submission Of Pre-Market Approval Application For IStent Inject Trabecular Micro-Bypass
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Glaukos Corp ::GLAUKOS ANNOUNCES SUBMISSION OF PRE-MARKET APPROVAL APPLICATION FOR THE ISTENT INJECT® TRABECULAR MICRO-BYPASS.GLAUKOS CORP- PLANS TO RELEASE EFFICACY AND SAFETY DATA FROM ISTENT INJECT TRABECULAR MICRO-BYPASS STENT TRIAL SOMETIME IN FIRST HALF OF 2018.  Full Article

Glaukos To Begin Randomized U.S. IDE Pivotal Clinical Trial For iStent SA System
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Glaukos Corp ::GLAUKOS TO BEGIN RANDOMIZED U.S. IDE PIVOTAL CLINICAL TRIAL FOR THE ISTENT SA™ SYSTEM.GLAUKOS SAYS U.S. FDA IS ALLOWING CO TO MOVE FORWARD WITH U.S. IDE PIVOTAL STUDY OF ITS ISTENT SA TRABECULAR MICRO-BYPASS SYSTEM.  Full Article

Glaukos Corp posts Q3 earnings per share $0.04
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Glaukos Corp :Glaukos Corporation announces third quarter 2017 financial results.Q3 earnings per share $0.04.Q3 sales $40.4 million versus I/B/E/S view $39.1 million.Q3 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S.Sees FY 2017 sales $155 million to $160 million.  Full Article

Glaukos Corp Q2 earnings per share $0.06
Tuesday, 2 Aug 2016 

Glaukos Corp : Glaukos corporation announces second quarter 2016 financial results . Q2 sales $28.6 million versus i/b/e/s view $24.5 million . Sees fy 2016 sales $105 million to $107 million . Q2 earnings per share $0.06 . Q2 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S . Says net sales rose 61% in q2 of 2016 to $28.6 million .Says revised guidance implies growth in 2016 net sales of approximately 46% to 49%, compared to 2015..  Full Article

BRIEF-Glaukos Q1 Loss Per Share $0.08

* GLAUKOS CORP ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS